In breast cancer there is evidence that a subset of HER2-negative patients can still respond to Trastuzumab and it has been postulated that undetectable sub populations of HER2 positive cells within HER2 negative tumours are responsible for tumour growth re-initiation [39–41]. Here, ERBB2 is linked to breast cancer.